News | Women's Health | September 25, 2017

Survey of breast cancer clinic patients finds short- and long-term side effects often better than anticipated; nine in ten women say radiation “less scary” than expected

Breast Cancer Patients Largely Find Radiation Therapy Experience Better Than Expected

September 25, 2017 — A new survey finds breast cancer patients’ actual radiation therapy experiences largely exceeded their expectations. The survey, which addressed the fears and misconceptions regarding radiation therapy for breast cancer, found that more than three-fourths of the breast cancer patients surveyed found their experiences with radiation therapy, including overall and specific long-term and short-term side effects, to be less “scary” than anticipated, according to research presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego.

“Radiation oncologists know firsthand that our patients come in with fears and sometimes misconceptions. Unlike many other treatments and fields of medicine, it is very hard to imagine what radiation therapy is like,” said Narek Shaverdian, M.D., lead author of the study and a radiation oncology resident at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). “Still, it is surprising to find that upwards of 90 percent of women surveyed agree that if future patients knew the reality of the radiation therapy experience, they would be less afraid of treatment.

“Advances in radiation therapy technologies over the past several decades and the increased use of hypofractionation — where radiation is given in larger doses across fewer sessions — have afforded patients more convenient treatment options, as well as lower toxicity rates in many situations,” said Shaverdian.

“Our study shows that women who received modern breast radiation therapy overwhelmingly found the treatment experience far better than expected. The negative stories out there are frightening and pervasive, but they generally are not reflective of the actual experience,” said Susan McCloskey, M.D., MSHS, assistant professor at the David Geffen School of Medicine at UCLA, director of the Breast Service at UCLA Radiation Oncology and senior author of the study.

Surveys were sent to all patients who received treatment for breast cancer at a UCLA-affiliated multidisciplinary breast cancer clinic between 2012 and 2016. Eligible patients had six or more months of follow-up and were without tumor recurrence. Sixty-five percent of these 502 patients returned surveys, and study findings are based on these 327 responses. The median age of survey respondents was 59 years (range 28-89 years).

Patients represented various disease stages; 18 percent had stage 0 breast cancer; 38 percent stage I; 34 percent stage II; and 9 percent stage III. Eighty-two percent underwent breast conserving surgery, 13 percent had axillary dissection, 37 percent received chemotherapy and 70 percent received endocrine therapy. All patients received radiation therapy (RT), delivered as either standard whole-breast RT with or without regional nodal coverage, hypofractionated whole-breast RT, post-mastectomy RT or partial breast RT.

Patients completed the survey a median of 31 months (range 6-61 months) after completing radiation therapy. Survey questions assessed fears and beliefs about breast cancer treatment and side effects, as well as how the actual experience compared to initial expectations. Specifically, patients were asked if the treatment experience, short-term side effects and long-term side effects were as expected, worse than expected or better than expected.

Nine in ten patients (90 percent) found the actual experience of breast radiation therapy to be “less scary” than anticipated. Overall short-term and long-term side effects of radiation were better than expected or as expected for 83 percent and 84 percent of respondents, respectively. Patients also reported that side effects were less severe than or as expected for short-term breast pain (75 percent), skin changes (61 percent) and fatigue (78 percent), as well as for long-term appearance changes (85 percent), breast pain (79 percent), breast size changes (73 percent) and breast textural changes (70 percent).

More than two-thirds (68 percent) of these breast cancer patients reported that they had little to no prior knowledge of radiation therapy at the time of their diagnosis, yet nearly half (47 percent) also shared that they had previously read or heard “frightening” stories of serious side effects from radiation therapy. Nearly all women surveyed (94 percent) responded that they were initially fearful of receiving radiation therapy. The most common initial fears related to radiation therapy were concerns about damage to internal organs (40 percent), skin burning (24 percent) and becoming radioactive (7 percent). Very few patients found confirmation for these negative stories during treatment, however; among 327 respondents, eight women (3 percent) found the negative stories they previously read about radiation therapy to be true and six women (2 percent) found the negative stories they heard from family and friends to be true. The trend of finding negative stories to be largely untrue was even more pronounced among patients who underwent breast conservation therapy. Nine in ten survey respondents agreed that “After treatment, I now realize that radiation therapy is not as bad as they say it is,” and/or that “If future patients knew the ‘real truth’ about radiation therapy, they would be less scared about treatment.”

“We hope that these data, which reflect the voices of past breast cancer patients, can help to counsel future patients and their physicians on the actualities of the modern breast radiation therapy experience,” said Shaverdian. “Patients who have received this treatment provide the most credible account of its actual impact, and their accounts show that outdated, negative stereotypes of breast radiation are almost universally found to be untrue.”

For more information: www.astro.org

Related Content

Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017


Related Content

News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
News | Mammography

April 11, 2024 — Volpara Health Technologies Ltd., a global leader in software for the early detection and prevention of ...

Time April 11, 2024
arrow
News | Society of Breast Imaging (SBI)

April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today ...

Time April 11, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
Subscribe Now